A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia Meeting Abstract
| Authors: | Tallman, M. S.; Feingold, J. M.; Spira, A. I.; Rizzieri, D.; Atallah, E. L.; Stock, W.; Jain, N.; Walter, R. B.; Chung, K. Y. |
| Abstract Title: | A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 392s |
| Language: | English |
| ACCESSION: | WOS:000404711504206 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.TPS7071 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS7071 -- Source: Wos |
